Treatment discontinuation rates due to lack of efficacy through 1 year of maintenance treatment with vedolizumab or subcutaneous infliximab in patients with inflammatory bowel disease: a systematic literature review and meta-analysis
Treatment discontinuation rates due to lack of efficacy through 1 year of maintenance treatment with vedolizumab or subcutaneous infliximab in patients with inflammatory bowel disease: a systematic literature review and meta-analysis
Jordi Guardiola, Perttu Arkkila, Jørgen Jahnsen, Stephen B. Hanauer et al.
Journal
Therapeutic Advances in Gastroenterology
Topics
Inflammatory Bowel Disease
article
Treatment discontinuation rates due to lack of efficacy through 1 year of maintenance treatment with vedolizumab or subcutaneous infliximab in patients with inflammatory bowel disease: a systematic literature review and meta-analysis
Jordi Guardiola, Perttu Arkkila, Jørgen Jahnsen, Stephen B. Hanauer, Walter Reinisch, Raja Atreya, Laurent Peyrin‐Biroulet, Silvio Danese, Philip J Smith, Alessandro Armuzzi, Seungmin Kim, Roberto Faggiani, Kiyeun Nam, Taek Sang Kwon, Jean–Frédéric Colombel, Marc Ferrante
article en
Abstract
No abstract available for this paper.
Publication Tag
Therapeutic Advances in GastroenterologyVol. 18
Institutions
Northwestern University (US), University of Helsinki (FI), Humanitas University (IT), University of Liverpool (GB), Vita-Salute San Raffaele University (IT), Inserm (FR), Friedrich-Alexander-Universität Erlangen-Nürnberg (DE), Akershus University Hospital (NO), Helsinki University Hospital (FI), McGill University Health Centre (CA), Bellvitge University Hospital (ES), Royal Liverpool University Hospital (GB), Institut d'Investigació Biomédica de Bellvitge (ES), Universitätsklinikum Erlangen (DE), IRCCS San Camillo Hospital (IT), Clinique Hartmann (FR), Comprehensive Cancer Center Erlangen (DE), Clinique Ambroise Paré (FR), Centre Hospitalier Universitaire de Saint-Étienne (FR), Celltrion (South Korea) (KR), IRCCS Humanitas Research Hospital (IT), Nutrition-Génétique et Exposition aux Risques Environnementaux (FR), Universitat de Barcelona (ES), Medical University of Vienna (AT), Icahn School of Medicine at Mount Sinai (US), KU Leuven (BE)
Funders
Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Gilead Sciences, Biogen, Celgene, Celltrion, United European Gastroenterology, Samsung, Cilag